Literature DB >> 30855760

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Young-Hak Kim1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30855760     DOI： 10.1056/NEJMc1900407

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis.

Authors:  Xuewen Wang; Shijie Wu; Yaying Chen; Erqian Shao; Tingting Zhuang; Linbin Lu; Xiong Chen
Journal:  Front Pharmacol       Date:  2020-01-31       Impact factor: 5.810

Review 2.  [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].

Authors:  Di Zhang; Jiaqi Huang; Chufeng Zhang; Yan Guan; Qisen Guo
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-06-20

Review 3.  Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.

Authors:  Mariana Segovia-Mendoza; Susana Romero-Garcia; Cristina Lemini; Heriberto Prado-Garcia
Journal:  J Immunol Res       Date:  2021-01-07       Impact factor: 4.818

4.  Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR / ALK wild-type advanced non-small cell lung cancer.

Authors:  Xiao-Xiao Peng; Ruoying Yu; Xue Wu; Shu-Yu Wu; Can Pi; Zhi-Hong Chen; Xu-Chao Zhang; Cun-Yi Gao; Yang W Shao; Li Liu; Yi-Long Wu; Qing Zhou
Journal:  J Immunother Cancer       Date:  2020-01       Impact factor: 13.751

5.  New pathways in immune stimulation: targeting OX40.

Authors:  Bertrand Routy; Lisa Derosa; Carolina Alves Costa Silva; Francesco Facchinetti
Journal:  ESMO Open       Date:  2020-02-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.